{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006457","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.926545+00:00","generated_at":"2026-06-18T09:48:05.003560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Medical Q4 rev $49.8M (+49% YoY); FY rev $141.8M (+50%); FY23 guide $187-193M","bullets":["Q4 revenue $49.8M (+49% YoY); FY2022 revenue $141.8M (+50% YoY).","Q4 net loss ($4.4M) or ($0.08)/share; Adjusted EBITDA positive $0.3M (vs loss $4.0M in Q4 2021).","FY2022 net loss ($42.8M) or ($0.77)/share; Adjusted EBITDA loss ($23.7M).","Completed follow-on offering raising net proceeds $107.5M; cash & securities $81.3M at year-end.","FY2023 revenue guidance $187-193M (32-36% growth)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006457","json":"https://secwatch.observer/filing/0000950170-23-006457.json","markdown":"https://secwatch.observer/filing/0000950170-23-006457.md","text":"https://secwatch.observer/filing/0000950170-23-006457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/tmci-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:48:05.003560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17130a64037ae2238a3e8deb8e511437c43c21eb","claim":"TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $49.8 million, net income ($4.4) million, or ($0.08) per share, EPS ($0.08) per share.","evidence_excerpt":"of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$49.8 million"},{"label":"Net income","value":"($4.4) million, or ($0.08) per share"},{"label":"EPS","value":"($0.08) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"25744101459a6ef1bd9ae2854ec98a6b6e010972","claim":"TREACE MEDICAL CONCEPTS, INC. reported the year ended December 31, 2022 results: revenue $141.8 million, net income ($42.8) million, or ($0.77) per share, EPS ($0.77) per share.","evidence_excerpt":"Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. • Blended average revenue per Lapiplasty® procedure kit sold was $5,907, a 10% increase over the same period last year and a 2% increase sequentially.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$141.8 million"},{"label":"Net income","value":"($42.8) million, or ($0.77) per share"},{"label":"EPS","value":"($0.77) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}